logo
‘Highly contagious virus' prompts CDC travel alert

‘Highly contagious virus' prompts CDC travel alert

Yahoo2 days ago

The Centers for Disease Control (CDC) is warning international travelers that they should be fully vaccinated against a disease that has become 'an ongoing risk around the world.'
Since January 2025, the CDC received at least 62 reports of travelers who were contagious with measles, according to CBS News. This 'highly contagious virus' has been on the rise in many countries and can easily infect people through coughing and sneezing, making it readily transmissible to international travelers.
Symptoms for measles can be more than just a red and bumpy rash. People can also experience a high fever, cough, runny nose and red, watery eyes, according to the CDC. The disease can become severe at any age and lead to complications like pneumonia (infection of the lungs), encephalitis (swelling of the brain) and death. More common complications include ear infections and diarrhea.
Children under 5 years old, adults over 20, pregnant women and people with compromised immune systems are more likely to suffer from measles complications.
The disease can be caught in many travel settings including travel hubs like airports and train stations, airplanes and trains, tourist attractions and crowded events, the CDC warns.
The virus can linger in the air or on surfaces for up to two hours after an infected person has left an area. Infection occurs when individuals breathe in contaminated air or touch an infected surface and then touch their face. People can spread measles up to four days before their rash even appears.
'Infected travelers can bring the disease back to their home countries where it can spread rapidly among people who are not immune,' the CDC wrote.
In response, the CDC issued a 'level one' warning, advising travelers to 'practice usual precautions,' and emphasizing that all international travelers should be fully vaccinated against measles with the measles-mumps-rubella (MMR) vaccine. Travelers are at risk if they have not had measles in the past or haven't been fully vaccinated at least two weeks before departure.
Receiving two doses of a measles-containing vaccine is the best way to protect against the disease, the CDC states. This includes an early dose for infants 6 through 11 months old and a total of two doses at least 28 days apart for anyone 12 months old or older without adequate evidence of immunity. The agency noted that if an infant had one dose of MMR vaccine before their first birthday, they should follow the recommended routine childhood immunization schedule and get another dose at 12 to 15 months and a final dose at 4 to 6 years old.
Children 12 months old and older, teenagers and adults unsure of their immunity against measles should receive two doses of MMR vaccine at least 28 days apart before international travel. If a child receives a first dose of measles-mumps-rubella-varicella (MMRV), they can receive a dose of MMR at least 28 days later, according to the CDC. However, they would not be able to receive another dose of MMRV until three months after a prior MMRV dose.
Travelers unsure if they or their travel companions are fully protected against measles should schedule an appointment with their clinician at least six weeks before traveling, the health agency wrote. This allows ample time to get fully vaccinated if needed.
Read the original article on MassLive.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why opioid deaths are falling in Bexar County
Why opioid deaths are falling in Bexar County

Axios

time13 minutes ago

  • Axios

Why opioid deaths are falling in Bexar County

Drug-related deaths in Bexar County have dropped from pandemic-era highs, but are still above 2019 levels, CDC data shows. Why it matters: Fatal overdoses initially rose during the COVID pandemic, but have been falling since 2023 as naloxone, which reverses an opioid overdose, has become more widely available. Flashback: Narcan, the best-known name brand of the drug, was made available over the counter in 2023. It is standard issue for first responders and available in treatment centers and some public places. By the numbers: There were 179 opioid-related deaths in Bexar County in 2024, per provisional CDC data the city's Metro Health Department shared with Axios. That's down 33.5% from a high of 269 such deaths in 2022, though still above the 135 deaths in 2019. Bexar County saw 208 stimulant-related drug deaths in 2024, down 23% from 270 in 2023 and up from 109 in 2019. Opioids include drugs like fentanyl and oxycodone. Stimulants include drugs like methamphetamine and cocaine. Naloxone works only on opioid overdoses. What they're saying:"The fact that Narcan … can reverse someone who is actively dying and who would have died otherwise, is hugely the reason why we see these decreases," Jessie Higgins, San Antonio's chief mental health officer, told a City Council committee last month. Yes, but: While deaths are dropping, it's hard to tell whether drug use itself is falling; that's harder to measure, Higgins said. Between the lines: Other factors contributing to the decline could include increased availability of paper test strips that detect fentanyl in illicit or counterfeit drugs. These can reduce fatal overdoses that happen when people take fentanyl-laced pills that look like prescription drugs. Zoom out: Almost all states saw decreases in overdose deaths in 2024. Across Texas, there were an estimated 4,990 overdose deaths, a nearly 15% decrease from a year earlier. There were an estimated 80,391 drug overdose deaths in the U.S. last year — a drop of 27% from 2023. Reality check: Experts warn a Trump administration budget proposal that would cut health services threatens the decline. A group of doctors and experts on addiction warned lawmakers in a letter last month that "drastic" cuts to federal health agencies and their grant recipients could set back efforts to address overdoses, addiction and mental health. Experts are particularly concerned that budget cuts could hit addiction recovery programs in rural areas and impoverished urban neighborhoods, NPR reported. The other side: U.S. Customs and Border Protection "is cracking down on the flow of deadly drugs into our country," White House spokesperson Kush Desai said in an emailed statement. CDC spokesperson Cassie Strawn said that the drug overdose epidemic "remains a critically important health issue" in the U.S.

Joni Ernst's "we're all going to die" pushes MAGA's toxic Christian compassion on us all
Joni Ernst's "we're all going to die" pushes MAGA's toxic Christian compassion on us all

Yahoo

time31 minutes ago

  • Yahoo

Joni Ernst's "we're all going to die" pushes MAGA's toxic Christian compassion on us all

Sen. Joni Ernst, R-Iowa, certainly has absorbed the first rule of MAGA: You're never in the wrong as long as you're "triggering" the liberals. On Friday, she drew outrage from her constituents at a town hall in Butler County, Iowa, with her bizarre defense of taking away people's medical care to pay for tax cuts for billionaires: "Well, we're all going to die." The crowd, furious about her plans to vote for drastic cuts to Medicaid that will deprive millions of health care, booed her. Ernst, having absorbed Donald Trump's philosophy of always doubling down, responded on Saturday with a favorite lady MAGA trick: pretending to be stupid. "I made an incorrect assumption that everyone in the auditorium understood that, yes, we are all going to perish from this earth," she sneered while walking in a cemetery. "So I apologize, and I'm really, really glad that I did not have to bring up the subject of the tooth fairy as well." Ernst may play the mean bimbo for the camera, but she is aware that people aren't asking to live forever. They just don't want to die decades before their time, due to a lack of basic health care. But while most of the media focused on her act, her follow-up spin was, if anything, even more callous. She invoked Jesus Christ as the reason it's okay to let people die from easily preventable causes. "But for those that would like to see eternal and everlasting life, I encourage you to embrace my lord and savior, Jesus Christ," she smugly those whose understanding of Christianity is based on compassion and love, this comment was jarring. But Ernst understands the second rule of MAGA: their version of Christian "love" is cruelty. When Ernst was asked again about her comments by a CBS News reporter on Monday, she snapped. "I'm very compassionate," she barked while running for an elevator. Sarah Longwell of The Bulwark speculated on MSNBC that Ernst "must be having a nervous breakdown." That's doubtful, as Ernst drove to the cemetery, recorded herself, and likely had a younger staffer edit and post the video to Instagram. This was a deliberate choice, which makes more sense in light of the larger trend in white evangelical circles to redefine empathy as a "sin" and insist that unfeelingness is a higher form of compassion. As David French explained in the New York Times: At the same time, hard-right Christians began to turn against the very idea of empathy. Last year a popular right-wing podcaster, Allie Beth Stuckey, published a best-selling book called 'Toxic Empathy: How Progressives Exploit Christian Compassion.' This month, a right-wing theologian, Joe Rigney, is publishing a book called 'The Sin of Empathy: Compassion and Its Counterfeits.' These Christians claim that true compassion comes from rejecting empathy, arguing that empathy gets in the way of speaking what they believe are "hard truths" they need to browbeat alleged sinners with. This is how the conservative Christian convinces himself it's love to deny LGBTQ people their freedom, because compelling heterosexuality will get them into heaven. Or to believe it's compassion to scream invective at a woman entering an abortion clinic, which gets reimagined as "counseling" the women to stop sinning. These are the rationalizations of people who want to hate while denying they are hateful. Ernst's behavior also shows how it can be used to justify opposition to Republican hostility towards Jesus' call to care for the poor and the disabled, especially if doing so means a slightly higher tax rate for the wealthy. Holly Berkley Fletcher, the author of the upcoming book "The Missionary Kids: Unmasking the Myths of White Evangelicalism," explained this in her Monday newsletter. Evangelicals tell themselves they "prioritize saving souls for eternity over helping bodies in the here and now," she wrote. In reality, of course, it's a way "to avoid responsibility and reform and to serve their own interests." Ernst's implication that people should welcome suffering and death has a long and ignoble history. Fletcher notes slave owners used this message to bully enslaved people in the 19th century. In recent years, the idea was revived due to the COVID-19 pandemic as a way to justify Republican opposition to life-saving measures like social distancing, masks, and eventually, vaccination. By October 2020, Tucker Carlson of Fox News was sounding this message, declaring, "At some point we are all going to die. Dying is the central fact of life," and suggesting that was reason enough to pull back all public health measures. It was a message that got a huge boost from evangelicals, especially pastors at megachurches who didn't want to put church services online, depriving them of the adulation of the adoring crowd. Rev. Tony Spell of Louisiana drew headlines in early 2020 by declaring, "True Christians do not mind dying." Caleb Mathis, pastor at the enormous Crossroads Church of Ohio, wrote at the time, "I hope it's the end of the world," because he believes heaven "sounds pretty freakin' amazing." Even after the vaccine, Joy Pullman of The Federalist wrote an article titled, "For Christians, Dying From COVID (Or Anything Else) Is A Good Thing." In it, she argued, "There is nothing we can do to make our days on earth one second longer or shorter," and also "death is good." None of these folks live by their own pro-death rules, of course. They see a doctor or take other measures to protect their health. It's only when they're asked to help others, whether through vaccination or paying slightly more in taxes, that they find this duty in others to welcome death with a smile. But this is worse than the usual Republican hypocrisy. It also reflects the increasingly Christian nationalist bent of the GOP. They are explicitly arguing that everyone else has to live by their fundamentalist religious belief that death is good. You may be an atheist, a non-Christian, or a more liberal Christian who believes in healing the sick. Too bad for you. In the MAGA view, we're all members of their fanatical death cult, whether we like it or not. The good news is that Ernst's shut-up-and-die ideology is not popular, even with a lot of people who consider themselves conservative Christians. On Monday, Democratic state Rep. J.D. Scholten announced that he's challenging Ernst in the 2026 election. Scholten told the Des Moines Register, "When she doubled down on Saturday with her, I felt, very disrespectful comments, I was like, 'OK, game on.'" It's a long shot in a deep-red state, but Scholten has some advantages, including being the pitcher for the Sioux City Explorers. He also has a long history of advocating for universal health care, drawing a contrast with Ernst's nihilistic views. Iowa is considered conservative, but its voting population has a significantly higher percentage of elderly individuals compared to the rest of the country. They may be especially hostile to Ernst's suck-it-up-and-die message.

NanoViricides Measles Drug Development Animal Study is Imminent
NanoViricides Measles Drug Development Animal Study is Imminent

Associated Press

time35 minutes ago

  • Associated Press

NanoViricides Measles Drug Development Animal Study is Imminent

SHELTON, CT / ACCESS Newswire / June 4, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the 'Company'), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announces that it is forging ahead with its Measles drug development program. The Company has commissioned an animal trial to evaluate certain drug candidates in a lethal animal infection model. The Company has secured specially modified mice that bear the human form of CD150/SLAM protein that the Measles virus requires to enter cells. The Company will initiate the study as soon as the animals arrive and are acclimatized at the animal study laboratory. 'NV-387 actually cured lethal RSV infection in animals, and Measles is a cousin of RSV,' said Anil R. Diwan, Ph.D., President and Executive Chairman of the Company, adding, 'This gives us confidence that NV-387 will have strong activity against Measles virus as well.' NV-387 is a clinical stage broad-spectrum antiviral drug that is designed to act as a decoy of a cell, attacking the virus by presenting to it the very features that the virus requires for binding to the cell, and upon binding, destroying the virus particle so it cannot infect. Over 90-95% of human pathogenic viruses require the sulfated proteoglycan feature that NV-387 presents to the virus. There is no approved drug for the treatment of Measles virus infection. Recently, CDC included Vitamin A as part of the standard of care for Measles infection. Vitamin A is known to help malnourished children with Measles, but its role as supplementary addition to non-deficient patients is not known. CDC also recommended use of ribavirin in extreme cases as a last resort. Ribavirin is a toxic nucleoside analog and is not approved for treatment of Measles. Thus there is a clear unmet need for a Measles drug. NV-387, a clinical stage drug can be rapidly developed to meet this need. The animal study of effectiveness of NV-387 in h-SLAM-modified mice will provide important information regarding potential human effectiveness of NV-387 to treat Measles virus infection. Measles outbreaks have continued to expand in the US, reaching a record 1,088 confirmed cases across 33 jurisdictions from January 1 through May 29, 2025 according to CDC ( ). Europe has witnessed a dramatic ten-fold increase in measles cases last year, i.e. 2024, over 2023. Measles vaccination rates have been declining in the USA since the COVID pandemic, according to a June 3, 2025 Johns Hopkins University news report ( ). The average county-level MMR vaccination rate in the USA fell from 93.92% pre-pandemic to 91.26% post-pandemic, moving well below the 95% herd immunity threshold that is generally regarded as providing community or herd immunity. Additionally, Measles vaccine failure cases have also been increasing according to the European data, which is an important cause for concern. It is likely that the increase in vaccine failure rate may be due to the increase in a new genotype, D8 of the Measles virus, replacing the previous dominant B3 genotype. The B3 genotype is closer to the Measles vaccine live attenuated Enders-Edmonton 'Moraten' strain that has been used in the USA since 1968. The changing genotypes suggest that the Measles virus is likely drifting away from the current vaccine. In this global scenario, NV-387, the clinical stage broad-spectrum, host-mimetic antiviral nanomedicine drug could perhaps be the only currently available drug candidate to combat the Measles virus and disease. Measles cases in Europe were over 35,000 in 2024, an almost ten-fold increase from 2023, according to the annual report of European Center for Disease Prevention and Control (ECDC). Only approximately 87% of cases were in unvaccinated persons, and 13% of the cases were of vaccine failure, out of the cases with known vaccination status. The significant Measles vaccine failure rate observed in Europe is alarming, considering that the two-dose vaccine is supposed to be 97% effective. Overall, childhood vaccination in Europe was about 94% and declining. This rate is below the 95% considered the threshold for achieving 'herd' or community immunity. Given the various causes of vaccine failure, and of vaccine hesitancy, attaining 95% vaccine coverage cannot be considered a very probable solution for combating the Measles epidemic. An effective drug is needed to combat the epidemic. ABOUT NANOVIRICIDES NanoViricides, Inc. (the 'Company') ( ) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading 'Risk Factors' and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. The phrases 'safety', 'effectiveness' and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA. FDA refers to US Food and Drug Administration. IND application refers to 'Investigational New Drug' application. cGMP refers to current Good Manufacturing Practices. CMC refers to 'Chemistry, Manufacture, and Controls'. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for 'Active Pharmaceutical Ingredient'. WHO is the World Health Organization. R&D refers to Research and Development. Contact: NanoViricides, Inc. [email protected] Public Relations Contact: [email protected] SOURCE: NanoViricides press release

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store